Immunomedics (IMMU) Shares are Down -5.88%

Immunomedics (IMMU) has risen sharply, recording gains of 2.64% in the past 4 weeks. However, the stock has corrected -5.88% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 2.86% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 4.86% and the fifty day Moving Average is 4.98%. Immunomedics Inc. has dropped 41.13% during the last three month period . Year-to-Date the stock performance stands at -11.4%.


Immunomedics (NASDAQ:IMMU): On Fridays trading session , Opening price of the stock was $2.78 with an intraday high of $2.895. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $2.6. However, the stock managed to close at $2.72, a loss of 1.45% for the day. On the previous day, the stock had closed at $2.76. The total traded volume of the day was 1,078,262 shares.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Companys technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.